Niklas Klümper
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (16)
Objectives: The aim of this study was to assess the association of diabetes mellitus and its medications with overall response (ORR) and mortality or cancer-specific survival (CSS) in patients with metastatic urothelial cancer receiving enfortumab vedotin monotherapy. Methods: This multicentre retrospective cohort study was designed according to the guidelines for the synthesis of qualitative research (ENTREQ). Eligible patients were adults (≥18) years treated with enfortumab vedotin monotherapy for metastatic urothelial cancer between June 2024 and January 2025. A total of 125 patients were reported across 11 centres. Results: The cohort included 93 males (74.4%) and 32 females (25.6%), with a mean age of 68.3 years (SD 9.3). The primary tumour site was the bladder in 109 (87.2%) cases and the upper tract (UTUC) in 16 (12.8%) cases. Interestingly, medication with metformin was significantly associated with cancer-specific mortality (37.9% versus 77.8%; p = 0.019), while patients with insulin-dependent diabetes mellitus had a significantly better CSS (Log Rank = 0.004). Upon comparing only patients who already had diabetes mellitus and then received anti-diabetic medication, there was a significant association between patients with diabetes mellitus receiving metformin and a worse 3-month ORR (80.0% versus 55.6%; p = 0.039). Regarding the subpopulation of UTUC, cancer-specific mortality was significantly associated with metformin medication (p = 0.033). Conclusions: Despite recent reports that metformin has protective effects in urothelial cancer, our findings suggest that metformin use may be linked to worse responses and survival outcomes in patients treated with enfortumab vedotin monotherapy. Further research, particularly translational research into the underlying diabetic and pharmacologic pathways, is warranted.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes in PRIM (A) and MET (B). (C) depicts differential NECTIN-4 expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.
Year:
2025
Supplementary Table 1. Clinico-pathological characteristics of the UC progression PRIM-MET study cohort. BRA=brain metastasis; HEP=hepatic metastasis; LYM=non-locoregionary lymph node metastasis; OSS=bone metastasis; OTH= metastasis at other locations including soft tissue; PER=peritoneal metastasis; PUL=pulmonary metastasis.
Year:
2025
TCGA cholangiocarcinoma cohort survival analysis. Overall survival analysis with respect to gene expression of Her2 (ERBB2), Trop2 (TACSTD2), Her3 (ERBB3), folate receptor 1 (FOLR1), and Nectin4 (PVRL4) in TCGA Bile Duct Cancer (CHOL) dataset (36 primary tumor).
Year:
2025
Cholangiocarcinoma is a rare and aggressive cancer type with limited therapeutic options. Several novel antibody–drug conjugates (ADC) have demonstrated promising antitumor activity in solid tumors. This study aimed to investigate the expression and the potential prognostic role of the protein targets of the recently developed ADCs in cholangiocarcinoma. Moreover, the study aimed to establish patient-derived tumor organoids (PDO) and to employ them for in vitro ADC testing. We evaluated the expression of TROP2, NECTIN4, folate receptor 1, HER2, and HER3 via IHC in a cholangiocarcinoma tissue microarray ( n = 113) and analyzed the expression level with respect to clinicopathologic parameters. Furthermore, we generated cholangiocarcinoma PDO culture lines and used them to test the antitumor activity of ADCs in vitro . IHC analyses revealed that TROP2 was the most frequently expressed (91% of cases), followed by folate receptor 1 (51%), NECTIN4 (49%), HER3 (20%), and HER2 (7%). TROP2 showed moderate to high expression (H-score ≥100) in 74% of cases. No significant correlations with overall or disease-free survival, tumor grade, or tumor stage were observed. Six cholangiocarcinoma PDO lines were successfully established (55% success rate). All PDO lines expressed TROP2 concordantly with their parental tumors and showed growth inhibition (IC 50 = 0.1–0.4 μg/mL) in response to sacituzumab govitecan (TROP2-targeting ADC). This study reveals that TROP2 is widely expressed in cholangiocarcinoma. Moreover, it provides preclinical evidence for the potential of the use of sacituzumab govitecan as a novel therapeutic strategy in treating patients with cholangiocarcinoma.
Year:
2025
Cholangiocarcinoma is a rare and aggressive cancer type with limited therapeutic options. Several novel antibody–drug conjugates (ADC) have demonstrated promising antitumor activity in solid tumors. This study aimed to investigate the expression and the potential prognostic role of the protein targets of the recently developed ADCs in cholangiocarcinoma. Moreover, the study aimed to establish patient-derived tumor organoids (PDO) and to employ them for in vitro ADC testing. We evaluated the expression of TROP2, NECTIN4, folate receptor 1, HER2, and HER3 via IHC in a cholangiocarcinoma tissue microarray (n = 113) and analyzed the expression level with respect to clinicopathologic parameters. Furthermore, we generated cholangiocarcinoma PDO culture lines and used them to test the antitumor activity of ADCs in vitro. IHC analyses revealed that TROP2 was the most frequently expressed (91% of cases), followed by folate receptor 1 (51%), NECTIN4 (49%), HER3 (20%), and HER2 (7%). TROP2 showed moderate to high expression (H-score ≥100) in 74% of cases. No significant correlations with overall or disease-free survival, tumor grade, or tumor stage were observed. Six cholangiocarcinoma PDO lines were successfully established (55% success rate). All PDO lines expressed TROP2 concordantly with their parental tumors and showed growth inhibition (IC50 = 0.1–0.4 μg/mL) in response to sacituzumab govitecan (TROP2-targeting ADC). This study reveals that TROP2 is widely expressed in cholangiocarcinoma. Moreover, it provides preclinical evidence for the potential of the use of sacituzumab govitecan as a novel therapeutic strategy in treating patients with cholangiocarcinoma.
Year:
2025
Clear cell renal cell carcinoma (ccRCC) is characterized by marked histological heterogeneity, encompassing its vasculature. Here, we introduce PropSegNet, a learning-based algorithm that segments and classifies three distinct vascular patterns in CD31-stained tissue sections. Integrating transcriptomic features, our work identifies a trajectory from high- to low-branching vessel architecture that co-evolves with the loss of proximal tubular cell traits in tumor cells. Furthermore, low-branching vessels form niches enriched with T cells and antigen-presenting cells. Mechanistically, air-liquid-interface cultures of patient-derived tumor fragments confirm that low-branching vessel features associate with T cell infiltration resulting in reduced viability under IL-2 rich conditions. Post-hoc transcriptomic analyses from two phase III clinical trials demonstrate that patients with tumors exhibiting an inflamed, low-branching vascular phenotype benefit most from the addition of immune checkpoint inhibition to anti-angiogenic treatment. These findings provide a rationale for prospective evaluation of vascular patterns and vessel-immune cell niches as potential biomarkers in ccRCC.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (23)
Michael Hölzel
Director/MD, Professor
University Hospital Bonn
SARA DE MARTIN
University of Padova
Matthias Geyer
Director
University of Bonn
DANIELA GABBIA
University of Padua
Dagmar Wachten
Prof. Dr
University of Bonn
Glen Kristiansen
-
Johannes Brägelmann
Professor
University Hospital Bonn
Tobias Bald
Group Leader
University Hospital Bonn
Philipp Erben
Laboratory Head
University Medical Centre Mannheim
Oliver Hahn
Attending urologist
University Hospital Würzburg
Annemarie Uhlig
Staff
University Medical Center Göttingen
Jörg Ellinger
University Hospital Bonn
Fabian Hörst
University Hospital Essen
Kristina Schwamborn
Technical University of Munich
Jens Kleesiek
-
Maria A. Gonzalez‐Carmona
-
Philipp Krausewitz
-
Wilko Weichert
University Hospital Heidelberg
Christoph Kuppe
Professor
RWTH Aachen University
Laila Schneidewind
University of Bern
Steffen Rausch
University Hospital Tübingen
Viktor Grünwald
Director
University Hospital Essen
Alexander Effland
University of Bonn
Make your next move.
Prepare your application
Review drafts before you send them.